Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that lead to cancer cell proliferation. Incyte Corporation (NASDAQ:INCY) stock performance was -6.24% in last session and finished the day at $55.70. Traded volume was 3.43million shares in the last session and the average volume of the stock remained 1.83million shares. The beta of the stock remained 1.32. Incyte Corporation (NASDAQ:INCY) insider ownership is 1.00%.

Halozyme Therapeutics Inc. (NASDAQ:HALO) priced a 7,692,307 share secondary stock offering at $13.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday, the stock is now 6.4% higher than the offering price. Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped -7.98 percent to $12.46 Monday on volume of 2.96million shares. The intra-day range of the stock was $12.37 to $13.95. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $1.52billion.

Greene points to gene therapy as one of the major strategies being pursued to achieve a functional cure. Richmond, CA-based Sangamo Biosciences, Inc. (NASDAQ:SGMO) recently showed progress in its drive to modify the genes of HIV- positive patients and replicate the immunity that the “Berlin patient” acquired from his bone marrow donor. Greene says he values Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s work, but he expects that most of the world’s HIV-positive population won’t be able to pay for Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s multi-step procedure to modify the genes in blood cells of individual patients. Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s stock on Mar 24, 2014 reported a decrease of -7.26% to the closing price of $19.80. Its fifty two weeks range is $6.86 -$24.69. The total market capitalization recorded $1.25billion. The overall volume in the last trading session was 2.91million shares. In its share capital, SGMO has 61.86million outstanding shares.

Nektar Therapeutics (NASDAQ:NKTR) has earned an average rating of “Buy” from the eight analysts that are presently covering the stock, Analyst Ratings.Net reports. On Monday, shares of Nektar Therapeutics (NASDAQ:NKTR) dropped -5.13% to close the day at $12.75. Company return on investment (ROI) is -108.20% and its monthly performance is recorded as
-6.59%. Nektar Therapeutics (NASDAQ:NKTR) quarterly revenue growth is 18.49%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone